Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2017
A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Registry-linked trialOpen access · greenAbstract readClinical Trial, Phase IIClinical Trial, Phase IIIMulticenter Study
In one paragraph
Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01197560 (A Phase 2/3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Lenalidomide), which is not on this map. Cited by 90 papers, 6 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
90citing papers in PubMed, 6 pooled it
14.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 2/3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Lenalidomide (Revlimid ®) Versus Investigator's Choice in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Who cites it
90 citing papers in PubMed, 6 syntheses or guidelines pooled it, 164 citations in OpenAlex.
- Pooled it
- Efficacy and safety of lenalidomide in diffuse large B-cell lymphoma: a meta-analysis of randomized controlled trials.Clinical and experimental medicine · 2023Pooled it
- Efficacy of Salvage Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Including Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review and Meta-Analysis.Cancer research and treatment · 2023Pooled it
- Comparison of first-line treatments for elderly patients with diffuse large B-cell lymphoma: A systematic review and network meta-analysis.Frontiers in immunology · 2022Pooled it
- Efficacy and Safety of Lenalidomide Monotherapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma: Systematic Review and Meta-Analysis.Frontiers in oncology · 2021Pooled it
- A Systematic Review of the Clinical Efficacy of Treatments in Relapsed or Refractory Diffuse Large B Cell Lymphoma.Advances in therapy · 2020Pooled it
- Zanubrutinib combined with R-CHOP in previously untreated diffuse large B-cell lymphoma with specific gene alteration: a phase II study.Blood cancer journal · 2026Trial
- A multicenter phase 1/2 trial of lenalidomide and dose-adjusted EPOCH-R in MYC-associated DLBCL.Blood advances · 2025Trial
- Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL.Blood advances · 2023Trial
- Polatuzumab vedotin-based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience.Annals of hematology · 2022Trial
- Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Trial
- Trial
- Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study.Drug design, development and therapy · 2020Trial
- Trial
- Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study.Leukemia · 2019Trial
- From Divergent Pathogenesis to Precision Medicine: The Road to Targeted Therapy in HIV-Associated and HIV-Unrelated Diffuse Large B-Cell Lymphoma.Diagnostics (Basel, Switzerland) · 2026Review
- Phase 1 study of zanubrutinib plus lenalidomide for patients with relapsed/refractory diffuse large B-cell lymphoma.Blood advances · 2026Article
- Cell-of-Origin Subtype Predicts Response to Polatuzumab Vedotin in Large B-cell Lymphoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Primary testicular diffuse large B-cell lymphoma with gonadal vein tumor thrombus: A case report and review of the literature.World journal of clinical oncology · 2025Article
30 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 18 institutions in 8 countries.
Myron S CzuczmanRoswell Park Cancer Institute, Buffalo, New York. mczuczman@celgene.com.
Marek TrněnýDepartment of Hematology, Charles University Hospital, Prague, Czech Republic.
Andrew DaviesCancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
Simon RuleDepartment of Haematology, Derriford Hospital, Plymouth, United Kingdom.
Kim M LintonDivision of Molecular and Clinical Cancer Sciences, The Christie Foundation Trust, Manchester, United Kingdom.
Nina Wagner-JohnstonDivision of Oncology, Washington University School of Medicine, St. Louis, Missouri.
Randy D GascoyneCentre for Lymphoid Cancers, BC Cancer Agency, Vancouver, British Columbia, Canada.
Graham W SlackCentre for Lymphoid Cancers, BC Cancer Agency, Vancouver, British Columbia, Canada.
Pierre BroussetLaboratoire D'Anatomie Pathologique, Centre Hospitalier Universitaire Purpan, Toulouse, France.
David A EberhardDepartment of Pathology/Laboratory Medicine and Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.
Francisco J Hernandez-IlizaliturriRoswell Park Cancer Institute, Buffalo, New York.
Gilles SallesHematology Department, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Pierre-Benite, France.
Thomas E WitzigDepartments of Laboratory Medicine and Pathology and Hematology, Mayo Clinic, Rochester, Minnesota.
Pier Luigi ZinzaniInstitute of Hematology and Medical Oncology, University of Bologna, Bologna, Italy.
George W WrightBiometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Louis M StaudtLymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Yandan YangLymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
P Mickey WilliamsMolecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland.
Chih-Jian LihMolecular Characterization and Clinical Assay Development Laboratory, Leidos Biomedical Research Inc. and Frederick National Laboratory for Cancer Research, Frederick, Maryland.
Jacqueline RussoCelgene Corporation, Summit, New Jersey.
Anjan ThakurtaCelgene Corporation, Summit, New Jersey.
Patrick HagnerCelgene Corporation, Summit, New Jersey.
Pierre FustierCelgene Corporation, Boudry, Switzerland.
Dale SongCelgene Corporation, Summit, New Jersey.
Ian D LewisDivison of Haematology, Royal Adelaide Hospital and University of Adelaide, Adelaide, Australia.
Bristol-Myers Squibb (Switzerland) · CHBC Cancer Agency · CANational Cancer Institute · USRoswell Park Comprehensive Cancer Center · USCentre Hospitalier Universitaire de Toulouse · FRCharles University · CZDerriford Hospital · GBFrederick National Laboratory for Cancer Research · USHôpital Lyon Sud · FRLeidos (United States) · USMayo Clinic · USNational Institutes of Health · USRoyal Adelaide Hospital · AUThe Christie NHS Foundation Trust · GBUniversity of Bologna · ITUniversity of North Carolina at Chapel Hill · USUniversity of Southampton · GBWashington University in St. Louis · US
Funding
Clinical development of mechanism-based lymphoma therapiesZIABC011780 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI STAUDT, LOUIS · 2017 to 2025
$11.4MIntramural NIH HHS ZIA BC011780
Abstract
PubMed holds no abstract for this paper.
Indexed as
PrognosisAdultAgedAntineoplastic Combined Chemotherapy ProtocolsDeoxycytidineDisease-Free SurvivalEtoposideFemaleGemcitabineHumansKaplan-Meier EstimateLenalidomideLymphoma, Large B-Cell, DiffuseMaleMiddle AgedOrganoplatinum CompoundsDeoxycytidineEtoposideGemcitabineLenalidomideOrganoplatinum CompoundsOxaliplatinRituximabThalidomide
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT01197560ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.